77903-28-7 Usage
Uses
Used in Pharmaceutical Research:
5-methoxy-4-methylpyridin-3-amine is used as a potential candidate in pharmaceutical research for the development of new drugs. Its specific structural elements may allow it to target particular receptors or enzymes, which could be beneficial in treating various diseases or conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 5-methoxy-4-methylpyridin-3-amine serves as a building block for the production of other chemical compounds with similar structural features. Its presence in the synthesis process can contribute to the creation of novel molecules with potential applications in various industries.
Further research and experimentation are required to fully explore and exploit the properties and potential uses of 5-methoxy-4-methylpyridin-3-amine, ensuring its safe and effective application in the intended fields.
Check Digit Verification of cas no
The CAS Registry Mumber 77903-28-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,7,9,0 and 3 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 77903-28:
(7*7)+(6*7)+(5*9)+(4*0)+(3*3)+(2*2)+(1*8)=157
157 % 10 = 7
So 77903-28-7 is a valid CAS Registry Number.
77903-28-7Relevant articles and documents
Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections
Magee, Thomas V.,Ripp, Sharon L.,Li, Bryan,Buzon, Richard A.,Chupak, Lou,Dougherty, Thomas J.,Finegan, Steven M.,Girard, Dennis,Hagen, Anne E.,Falcone, Michael J.,Farley, Kathleen A.,Granskog, Karl,Hardink, Joel R.,Huband, Michael D.,Kamicker, Barbara J.,Kaneko, Takushi,Knickerbocker, Michael J.,Liras, Jennifer L.,Marra, Andrea,Medina, Ivy,Nguyen, Thuy-Trinh,Noe, Mark C.,Obach, R. Scott,O'Donnell, John P.,Penzien, Joseph B.,Reilly, Usa Datta,Schafer, John R.,Shen, Yue,Stone, Gregory G.,Strelevitz, Timothy J.,Sun, Jianmin,Tait-Kamradt, Amelia,Vaz, Alfin D. N.,Whipple, David A.,Widlicka, Daniel W.,Wishka, Donn G.,Wolkowski, Joanna P.,Flanagan, Mark E.
experimental part, p. 7446 - 7457 (2010/06/13)
Respiratory tract bacterial strains are becoming increasingly resistant to currently marketed macrolide antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safe
